To facilitate the clinical application of TUBA1B as a prognostic marker, we constructed a nomogram incorporating various clinicopathological factors, including TUBA1B expression, to better predict overall survival rates for glioma patients (Figure 2I). This evidence concerns the gene TUBA1B and central nervous system cancer.